Trial reportBreast cancer research and treatment2025
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial.
Trial report in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough triple-negative breast cancer (TNBC) is associated with increased risk for early locoregional (LRR) and distant recurrence (DR), it is unclear if there are racial differences in clinical outcomes. This study examines patterns of recurrence and breast cancer mortality (BCM) between Black and White women with high-risk TNBC treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) EA1311 randomized clinical trial.
methodsFrom 2015 to 2021, 415 patients with clinical stage II-III TNBC and residual disease after neoadjuvant chemotherapy (NAC) were randomized to adjuvant capecitabine or platinum chemotherapy. Overall, 363 patients with self-reported Black or White race were included in this analysis. LRR, DR, and BCM were analyzed by race using Kaplan-Meier curves for unadjusted estimates and Cox modeling for adjusted analyses.
resultsRacial distribution included 66 (18.2%) Black and 297 (81.8%) White patients. Disease presentation, response to chemotherapy, and treatment arm were similar by race. Two-year estimated LRR was 27.1% in Black and 17.3% in White patients (p = 0.378), and 2-year estimated DR and BCM were similar by race. Models adjusted for race, age, stage, grade, treatment arm, and locoregional therapy did not identify race as an independent predictor of LRR, DR, or BCM.
conclusionAmong women with residual TNBC after NAC treated on this trial, there were no significant differences in LRR, DR, or BCM between Black and White patients at 2 years of follow-up. Despite the small cohort and short-term follow-up, our results suggest that treatment on a clinical trial may mitigate disparities in disease outcomes in TNBC.
Indexed as
Identifiers
40759832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.